Curing blindness through regenerative cell therapies. We replace what is lost.

StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness.

We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery.

TechTour Europe Future 2022 Award Winner

The most innovative startup in health and life sciences in Europe at BioFit, 2020

Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022

EIT Health Catapult Biotech pitching competition Finalist StemSight

Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023

About us

The founding team of StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications. The scientific excellence is complemented by our distinguished board of accomplished industry leaders and advisors with extensive global business acumen.

4/8/2025

StemSight is part of the revolutionary €8 Million EU-Funded KeratOPrinter Project

StemSight is proud to join the EU-funded KeratOPrinter project, aimed at revolutionizing corneal transplantation. This groundbreaking initiative uses advanced bioprinting technology to create full-thickness, biocompatible corneas, addressing the global shortage of donor tissue.

The project is set to redefine corneal transplantation, making vision-restoring therapy more accessible, efficient, and sustainable. The collaborative effort, involving partners from five EU countries, promises to restore vision for millions.

16/12/2024

StemSight advances to EIC Accelerator interviews

As an innovative technology company focused on creating lasting benefits to the European health ecosystem, StemSight is a prime candidate for EU's EIC Accelerator funding. This highly competitive funding scheme requires two application phases, and a final interview. StemSight has been invited to the interview in front of an expert jury taking place in-person in Brussels in January 2025!

7/6/2024

Laura Koivusalo on stage at HLTH Europe

The legendary HLTH event lands in Amsterdam on the 17th-20th of June! Our CEO Laura is speaking on the Startup Stage on the final day of the event in the EIT Health Catapult panel.

6/5/2024

StemSight wins Dragon's Den competition at Finnish Biotechs & Investors meeting

Tesi, Innovestor and HealthCap co-organized the first Finnish Biotechs and Investors meeting, where StemSight participated in the Dragon's Den -type pitching competition. StemSight was selected as the winner from the pitching companies!

4/2/2025

Laura Koivusalo nominated for the European Prize for Women Innovators

Our CEO and founder Laura Koivusalo has been selected as one of the 6 semifinalists for the European Prize for Women Innovators in the Rising Innovators category. The Rising Innovators Prize celebrates exceptional women leaders under the age of 35.

26/9/2024

StemSight selected for BIO Europe Startup Spotlight finals

Europe's premier partnering event will be held in Stockholm on 4-6 November. StemSight has been selected as one of the 8 companies to pitch in the Startup Sportlight session in front of a panel of expert judges. Our CEO Laura Koivusalo will be on stage and available for partnering at the event.

29/4/2024

StemSight is presenting at Bio€quity 2024

On May 12 to May 15, our CEO Laura Koivusalo will be attending the Bio€quity biotech investor meeting in San Sebastian, Spain. Laura will give a presentation about StemSight and our latest achievements on May 14 at 11:00 as part of the Cell and Gene Therapy Track. Meetings with Laura can be requested through the event partnering system!

MORE NEWS